Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …

Background Now that immunotherapy plus chemotherapy (CT) is one standard option in first-
line treatment of advanced non-small cell lung cancer (NSCLC), there exists a medical need …

The evolution of therapeutic resistance is a major cause of death for cancer patients. The
development of therapy resistance is shaped by the ecological dynamics within the tumor …

Introduction A literature review was undertaken to identify clinical trials and real-world
studies of patients with stage IV NSCLC who had progressed on or after treatment with …

Abstract c-Met inhibitors are a class of drugs that include nonselective and selective
molecules. These drugs can differ in terms of pharmacodynamic and pharmacokinetic …

Discussion ROS1 inhibitors with reported clinical efficacy are crizotinib, ceritinib, entrectinib,
lorlatinib, and repotrectinb. Additionally, preclinical data showing some level of potency are …

Methods A comprehensive search of related articles was performed focused on phases Ⅱ
and Ⅲ clinical trials studies. Results The lung cancer management should take into …

During the last years, translational research has contributed in many advances in the
treatment of non-small cell lung cancer (NSCLC) discovering genetic alternations or …

Background. Multitargeted tyrosine kinase inhibitors (TKIs) represent a new class of target‐
specific antineoplastic agents. These agents show some specific adverse events such as …

Non-small cell lung cancer (NSCLC) is characterized by several molecular alterations that
contribute to its development and progression. These alterations include the epidermal …